What Анальгин-Ультра treats: main uses and benefits

The active ingredient, Metamizole, is applied in contexts marked by increased discomfort or tension. Its application includes the management of symptoms related to physical discomfort and systemic imbalance, such as moderate to severe pain and fever.

This therapeutic agent is generally considered relevant when supportive symptom management is appropriate for symptoms related to physical discomfort that create noticeable physiological strain. It is commonly used for distressing symptom clusters that may become intense or disruptive in conditions involving episodic or fluctuating manifestations, such as discomfort associated with colic, post-surgical recovery, and tumour-related pain. The agent may also play a role in managing symptoms linked to systemic imbalance, such as fever that requires additional symptomatic assistance.

This assistance is relevant for easing symptoms associated with acute or episodic changes, supporting a more steady management of symptom fluctuations and general well-being during symptomatic phases.

Quick Fact: Relevant for Symptoms related to Physical Discomfort

Regulatory References

1. European Medicines Agency referral page on Metamizole

Who can and cannot use Анальгин-Ультра?

Eligibility for Анальгин-Ультра (Metamizole Sodium) is strictly defined by regulatory bodies based on age, physiological status, and underlying medical conditions. The medicine is primarily approved for adults and adolescents from 15 years of age; however, some formulations are licensed for children from 3 months of age for specific indications.

Absolute Contraindications

Use is strictly prohibited for patients with a history of agranulocytosis or hypersensitivity to pyrazolone derivatives, as well as those with diseases of the haematopoietic system or Acute Hepatic Porphyria. It is also absolutely contraindicated in the third trimester of pregnancy and in infants under 3 months of age or 5 kg body weight.

Conditional Use and Restrictions

Use requires special caution for the elderly and individuals with pre-existing renal or hepatic impairment, often necessitating a dose reduction or avoidance of repeated high doses. The medicine is not recommended during the first and second trimesters of pregnancy. During lactation, repeated use is prohibited, and breast milk must be discarded for 48 hours following a single dose.

Interactions with other medicines and products

The active substance, Metamizole (Dipyrone), has documented interactions with several categories of medicinal products, primarily based on pharmacokinetic changes and pharmacodynamic effects.

Pharmacokinetic Interactions (Enzyme Modulation)

Metamizole has the potential to induce certain liver enzymes, specifically CYP2B6 and CYP3A4. This enzymatic induction can lead to reduced plasma concentrations and a subsequent decrease in the efficacy of co-administered medicines that are metabolized by these enzymes. Products affected include the following, where monitoring of clinical response or drug levels may be required:

• Immunosuppressants: Such as Ciclosporin and Tacrolimus.
• Antidepressants: Such as Bupropion and Sertraline.
• Other Agents: Such as Efavirenz, Methadone, and Valproate.

Pharmacodynamic and Other Specific Interactions

• Low-Dose Aspirin (Acetylsalicylic acid): Metamizole may interfere with the antiplatelet effect of low-dose aspirin used for cardiovascular protection. To minimize this interaction, a specific time interval between administrations is advised by regulatory guidance.
• Chlorpromazine: Co-administration with the antipsychotic Chlorpromazine may result in an increased risk of severe hypothermia (abnormally low body temperature).
• Antibiotics: The use of Metamizole concomitantly with certain antibiotics may mask the initial symptoms (e.g., fever) of a serious blood disorder called agranulocytosis. Immediate discontinuation and blood count monitoring are required if such symptoms develop.

How Анальгин-Ультра Works

Central Inhibition of Key Signal Mediators

The primary pharmacodynamic action of Metamizole involves modulating the synthesis of specific prostaglandins, which are chemical mediators of pain signal transmission and thermal regulation. The active metabolite primarily targets enzyme pathways within the central nervous system (CNS), initiating a sequence that reduces the concentration of these mediators. This mechanism contributes to the modulation of pain signal processing and thermoregulation by influencing the hypothalamic set point.

---

Modulation of Descending Neural Pathways

Beyond the central enzyme inhibition, the drug engages mechanisms that influence descending neural pathways involved in the transmission of pain signals. This includes interaction with the body's intrinsic opioidergic and cannabinoid systems, which results in the modulation of overactive signals within these pathways. This targeted pathway adjustment influences nociceptive signaling, contributing to the overall modification of sensory input.

---

Direct Relaxation of Smooth Muscle

A distinct mechanistic domain involves its direct spasmolytic effect on visceral smooth muscle tissue. This mechanism is thought to involve altering cellular calcium handling, initiating signaling sequences that lead to a rapid reduction of excessive muscle tone. This action results in the reduction of hypercontractility within targeted peripheral pathways.

The parameters for using Metamizole Sodium, the active ingredient in Анальгин-Ультра oral tablets, involve specific patterns for administration and dosing. A standard principle involves beginning therapy with the lowest effective dose.

Administration Scope

Instruction	Detail
Route of administration	Oral use. The medicine is supplied as a film-coated tablet.
Dosing schedule	For adults and adolescents ge 53 kg (age ge 15 years), a single dose ranges from 500 mg to 1,000 mg. The absolute maximum oral daily dose is 4,000 mg.
Timing in relation to meals (if applicable)	Generally taken with or without food.
Preparation requirements (if applicable)	The tablet is swallowed whole with an adequate amount of liquid.
Age-group administration rules	Pediatric: Single doses for children are calculated based on body weight, typically 8 mg/kg to 16 mg/kg. Older Adults: A reduced dosage is often used due to the potential for delayed clearance of metabolites.
Missed-dose rules	If a dose is missed, the subsequent dose is scheduled to observe the minimum interval of 6 to 8 hours.
Special procedural conditions	The avoidance of multiple high doses is relevant for patients with renal or hepatic impairment, though short-term use may not require reduction.

Instruction Classifications (High-Level)

Classification	Detail
Administration method type	Oral
Frequency pattern	As-needed (intermittent), up to four times daily.
Standard basis	Harmonized pharmacological parameters.
Use-context constraints	Short-term use for the acute phase of symptoms.

Resulting Procedural Structure

Step sequence:

• Administration of the lowest effective dose of the oral tablet.
• The tablet is swallowed whole with liquid.
• Repeating the dose occurs only when required, maintaining a minimum 6 to 8 hour interval.

Connection to the overall use protocol: The application of this medicine follows an oral, short-term method for symptom management, characterized by specific numerical dosing limits and time separation between administrations. This framework includes constraints on total daily intake and involves dose modification for older adults or individuals with impaired organ function.

Research Evidence / Overview of studies for Анальгин-Ультра

This overview describes the scope of the scientific research conducted on the active ingredient in Анальгин-Ультра (Metamizole). It focuses on the types of studies that exist, the aspects they explored, and what remains uncertain in the evidence, without providing any clinical advice or making claims about personal outcomes.

Evidence for Managing Acute Pain and Fever

The research base for Metamizole includes numerous Randomized Controlled Trials (RCTs) and scientific meta-analyses. These studies primarily examine the use of the medicine for short-term, temporary symptom relief in acute conditions.

Studies on Postoperative Pain Relief

Research has explored the use of Metamizole in adults following various surgical procedures. These short-term RCTs were applied in studies examining patient-reported experiences and monitored outcomes related to physical discomfort, primarily focusing on measurements of pain intensity scores and the requirements for additional pain medication.

Findings describe patterns observed in the studies related to changes in acute pain scores within the immediate post-surgical period. Research highlights changes measured during the study period concerning the need for supplemental pain relief in the trial populations. However, most of this research concentrates on the effect of a single dose or treatment lasting less than a week.

Studies on Fever Reduction

Metamizole was evaluated in studies addressing fever in both febrile children and adults. These trials monitored outcomes related to systemic or functional imbalance by tracking changes in body temperature at specific intervals.

Studies report how symptoms evolved in the observed populations, and findings often described similar short-term antipyretic patterns in trials where other agents were also studied. The research provides insight into short-term changes in temperature. This evidence, however, is narrowly focused on the acute reduction of temperature.

Evidence for Pain Associated with Spasm (Colic)

Research has focused on the use of Metamizole in studies involving pain associated with smooth muscle contraction, including conditions identified as colic.

Research on Other Acute Pain Contexts

Systematic reviews and clinical trials was evaluated in adults experiencing acute pain related to muscle spasm. These studies examined outcomes related to physical discomfort and the need for further medical intervention. Findings describe patterns observed in the studies related to measurements of pain intensity and the requirement for subsequent pain relief during the acute episode.

In addition, Metamizole was evaluated in conditions characterized by episodic or acute changes, such as headache and migraine episodes. These studies monitored outcomes related to pain intensity and the return of symptoms within a short timeframe.

Evidence Gaps and Areas of Uncertainty

It is important to understand the boundaries and limitations of the existing research for Metamizole:

• Long-term effects are not fully established: Most research is designed to evaluate short-term outcomes, meaning that follow-up durations were limited. There is limited information for long-term outcomes regarding the persistence of observed changes or patterns of recurrence for conditions characterized by fluctuating or episodic manifestations.
• Data for certain groups remain insufficient: While Metamizole was evaluated in children and older adults, specific findings for patients with certain complex or multiple health conditions are limited, and comparative evidence is not consistently available for many potential patient subgroups. The results apply only to the populations studied in the trials.

Common questions about Анальгин-Ультра (FAQ)

---

Q: How does Анальгин-Ультра work?

Official product information states that this medicine acts as a non-narcotic analgesic (pain reliever), antipyretic (fever reducer), and spasmolytic (smooth muscle relaxant). It works primarily by inhibiting the signals of pain and fever in the central nervous system (brain and spinal cord). The ability to relax smooth muscle is a key difference from many general painkillers.

---

Q: Is it normal to feel a bit dizzy after taking Анальгин-Ультра?

Dizziness, or vertigo, is listed in regulatory documents as a possible adverse effect. Furthermore, a drop in blood pressure (hypotension) is a known side effect that can cause feelings of lightheadedness. If this symptom is severe or persistent, it is important to contact a healthcare professional.

---

Q: Can you take Анальгин-Ультра if you have stomach problems like gastritis?

Official regulatory guidelines often contraindicate or advise caution when using Metamizole in individuals with certain chronic gastrointestinal disorders, including ulcers. Individuals with such conditions are advised to consult a healthcare professional regarding the suitability of this medication.

---

Q: Is there a maximum number of days in a row you should take Анальгин-Ультра?

The medicine is intended for short-term use for the acute phase of symptoms. Official guidelines require regular monitoring of blood counts if treatment is prolonged beyond a short, acute period.

---

Q: What happens if I accidentally take Анальгин-Ультра on an empty stomach?

The official product information states that the medicine can generally be taken with or without food. There is no specific regulatory warning against taking the tablet on an empty stomach.

---

Q: Are there any food or drinks that should be avoided when taking Анальгин-Ультра?

Yes, alcohol consumption should be avoided while taking Metamizole, as this combination can increase the risk of certain side effects, including potential stomach issues.

---

Q: Does taking Анальгин-Ультра affect the ability to drive or operate machinery?

Yes, regulatory labels advise caution because Metamizole can cause side effects such as drowsiness, fatigue, or low blood pressure. It is officially recommended that patients do not drive or operate machinery until they know how the medicine affects them personally.

---

Q: Is Анальгин-Ультра safe for use in older adults (seniors)?

Official information states that the dose must often be reduced in elderly people due to the potential for delayed elimination of the drug’s metabolic products from the body. Close monitoring is required for this age group.

---

Q: What should I do if I forget to take a dose of Анальгин-Ультра?

If a dose is missed, the subsequent dose must still observe the minimum dosing interval, which is typically 6 to 8 hours. Patients should never take a double dose to make up for a forgotten one.

---

Q: Are there any known severe allergic reactions associated with Анальгин-Ультра?

Yes, regulatory documents note that Metamizole has been associated with severe, very rare allergic reactions. These include anaphylactic shock (a life-threatening reaction) and serious skin conditions like Stevens-Johnson Syndrome (SJS).

---

Q: What evidence or research supports the use of Анальгин-Ультра for muscle pain?

The medicine possesses a spasmolytic (smooth muscle relaxing) effect. For this reason, regulatory information and studies indicate its use for pain associated with smooth muscle spasms, which includes certain types of muscle pain.

---

Q: Why does the packaging for Анальгин-Ультра warn about blood cell counts?

Warnings are present because the medicine carries a rare but serious risk of severe blood disorders, particularly agranulocytosis (a severe reduction in white blood cells). Official patient information requires that treatment be discontinued and medical attention sought if specific concerning symptoms develop.

---

Q: Is Анальгин-Ультра primarily for acute pain or can it be used for chronic conditions?

Official therapeutic indications state that the medicine is primarily for the short-term treatment of moderate to severe acute pain and high fever. There is generally insufficient experience available for long-term use in chronic conditions.

---

Q: Does AnaIgin-UItra interact with alcohol, and how severe is the interaction?

Official product information advises avoiding alcohol consumption while taking Metamizole. This is because alcohol can increase the risk of potential side effects, including gastrointestinal problems.

---

Q: Is it true that Анальгин-Ультра is banned or restricted in some countries?

Yes, this is true. Due to the risk of agranulocytosis, some national authorities, such as those in the US and UK, have not approved or have withdrawn Metamizole. However, it remains approved and regulated in several European and Latin American countries under strict conditions.

---

Q: What are the signs of an overdose with Анальгин-Ультра?

Symptoms of an overdose, as listed in the regulatory documents, can include gastrointestinal issues such as nausea, vomiting, and abdominal pain. Other potential signs are somnolence (drowsiness), vertigo, and signs of kidney dysfunction.

---

Q: Can people with liver or kidney problems take a reduced dose of Анальгин-Ультра?

As the elimination rate may be reduced, multiple high doses should be avoided in patients with impaired kidney or liver function. While short-term use may not require a reduction, prolonged use requires close medical supervision.

---

Q: Why might a doctor prescribe Анальгин-Ультра instead of a more common analgesic?

Regulatory documents indicate the medicine is typically reserved for severe pain or fever when other common treatments are not suitable or have failed. The drug's unique ability to relieve pain associated with muscle spasm is another factor that may influence prescribing decisions.

---

Q: Does Анальгин-Ультра have any effect on sleep or mood?

While not a primary indication, regulatory documents list somnolence (drowsiness) as a possible adverse effect in some patients, and it can occur as a symptom in the event of an overdose.

---

Q: Are there any studies on the long-term safety of Анальгин-Ультра?

Most clinical experience and studies are focused on short-term outcomes. Official guidelines note that there is limited or insufficient experience available with the long-term, repeated use of Metamizole, particularly in patients with severe organ impairment.

---

Q: Why is Analgin-based medication sometimes controversial?

The primary reason for controversy is the association of the active ingredient, Metamizole, with the rare but potentially fatal side effect of agranulocytosis (a severe blood disorder). This risk has led to its withdrawal or restriction in several countries.

---

Q: Is it common for Анальгин-Ультра to cause a change in urine color?

Official patient information states that the urine may turn a harmless red color due to a metabolite of the medicine. This is a common, non-clinical sign and is not considered a true adverse effect.

---

Q: What is the typical duration of treatment with Анальгин-Ультра for a short-term issue?

The duration of administration depends on the specific illness, but it is strictly intended for short-term, acute phase use only. If symptoms continue or treatment is prolonged, the manufacturer recommends regular monitoring of blood count.

---

Q: Are there specific symptoms that mean I should stop taking Анальгин-Ультра immediately?

Yes. If symptoms of a serious blood disorder appear, such as fever, chills, sore throat, or painful sores on the gums/mouth lining, the medicine must be discontinued immediately, and prompt medical attention should be sought.

---

Q: How does Анальгин-Ультра affect the body's clotting mechanism?

Metamizole can interfere with the antiplatelet effect of low-dose aspirin used to prevent cardiovascular events. To minimize this effect, official guidance advises that a specific time interval should be observed between taking the two medicines.

---

Q: Is it true that Анальгин-Ультра can sometimes cause skin rashes?

Yes, regulatory documents list general skin rashes (urticaria) as a possible adverse effect. More severely, but rarely, it can cause life-threatening skin reactions like Stevens-Johnson Syndrome.

---

Q: What is the difference between Analgin and metamizole?

Metamizole, often called Dipyrone, is the active chemical substance (the INN) in the medicine. Анальгин-Ультра is a specific brand name or proprietary medicinal product that contains Metamizole Sodium.

---

Q: Is AnaIgin-UItra effective for treating joint pain and inflammation?

Official information describes the medicine as having a strong analgesic (pain-relieving) and antipyretic effect, but only a low or limited anti-inflammatory effect. Therefore, it is generally not indicated for chronic inflammatory conditions like arthritis.

---

How to Store and Dispose of Analgin-Ultra

Official regulatory information for Metamizole Sodium (the active substance) defines strict constraints for its storage and disposal.

Storage Requirements

Storage Classification	Official Statement
Temperature & Environment	Store in a cool and dry place, and keep the container tightly closed.
Protection	Requires storage locked up (P405) to prevent unauthorized access. The substance must be protected from incompatible materials and the formation of dust.
Handling	Must be handled in a well-ventilated area. Contact with the skin and eyes should be avoided.

Disposal Instructions

Disposal Method	Official Statement
General Rule	Dispose of the product and container through a waste management company authorized by the local government or a licensed chemical destruction plant.
Environmental Rule	Avoid discharge into drains, water courses, or onto the ground. Do not release the product into the environment.

These mandates ensure the drug's stability, prevent unauthorized access, and establish a regulated pathway for final destruction, prohibiting disposal via common sewage or household waste.